Arcellx (ACLX) Competitors

BeiGene (NASDAQ:BGNE) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Do insiders & institutionals believe in BGNE or ACLX?

48.6% of BeiGene shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 7.4% of BeiGene shares are held by insiders. Comparatively, 6.2% of Arcellx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to BGNE or ACLX?

In the previous week, BeiGene had 16 more articles in the media than Arcellx. MarketBeat recorded 31 mentions for BeiGene and 15 mentions for Arcellx. Arcellx's average media sentiment score of 0.45 beat BeiGene's score of 0.25 indicating that Arcellx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeiGene	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcellx	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, BGNE or ACLX?

BeiGene has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Do analysts rate BGNE or ACLX?

BeiGene currently has a consensus target price of $247.07, suggesting a potential upside of 30.57%. Arcellx has a consensus target price of $103.08, suggesting a potential upside of 17.36%. Given BeiGene's higher possible upside, equities analysts plainly believe BeiGene is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeiGene	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arcellx	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07

Does the MarketBeat Community prefer BGNE or ACLX?

BeiGene received 482 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.05% of users gave Arcellx an outperform vote while only 69.29% of users gave BeiGene an outperform vote.

Company	Underperform	Outperform
BeiGene	Outperform Votes 546 69.29%	Underperform Votes 242 30.71%
Arcellx	Outperform Votes 64 82.05%	Underperform Votes 14 17.95%

Is BGNE or ACLX more profitable?

Arcellx's return on equity of -8.28% beat BeiGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeiGene	-25.94%	-25.12%	-14.95%
Arcellx	-25.94%	-8.28%	-5.21%

Which has stronger earnings and valuation, BGNE or ACLX?

Arcellx has lower revenue, but higher earnings than BeiGene. Arcellx is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeiGene	$2.46B	7.50	-$881.71M	-$8.24	-22.96
Arcellx	$110.32M	43.06	-$70.69M	-$0.71	-123.70

Summary

Arcellx beats BeiGene on 11 of the 18 factors compared between the two stocks.